Character expects 'disappointing' first half

But supplier expects to bounce back in FY2013 with sales from new toy lines.
Author:
Publish date:
5_Appgear foam fighters.jpg

Character Options has said that it will 'not be in a position' to achieve the market forecasts for the financial year ending August 31st 2013.

The toy supplier expects its 2013 first half sales to fall 'materially short' of its budgeted sales to Christmas, blaming an 'abnormally difficult' market and poor demand for certain toy lines in its portfolio.

While licensed ranges including Peppa Pig, Fireman Sam and Scooby Doo performed well, third-party lines like Zhu Zhu Pets and Squinkies saw demand fall away ‘much faster than anticipated’. App toy brand AppGear also underperformed (AppGear Foam Fighters pictured).

Speaking in a trading update ahead results for the financial year ending August 31st 2012, Character Options said: “[We expected] AppGear, which was thought by the trade to be one of the hottest new categories within the industry, to achieve a niche position but sales to date have fallen well short of expectations.”

Character said it was optimistic that it could generate stronger sales in the calendar year 2013, commenting that its Bin Weevils, Angry Birds and Construct-a Bugz toy lines each had great sales potential. Premier League football construction line, Character Building Sports Stars, has also made ‘a solid start with encouraging sales’.

Want to receive up to the minute toy industry news straight to your inbox? Click here to sign up for the free ToyNews Daily Digest and Newsflash services. You can also follow ToyNews on Twitter and Facebook.

Related

Featured Jobs

Copyrights Group

Marketing Manager

The Copyrights Group is one of the licensing arms within The Vivendi Group. Acquired by Vivendi in 2016 Copyrights manages the licensing for a portfolio of properties to include Paddington Bear. Some of the other companies within the Vivendi Group include Universal Music Group, and their licensing arm Bravado, Gameloft and Studiocanal to name a few.